BCIQ Profiles

Company Profile ReportTarget Profile Report
1019 Nimbus
BioCentury & Getty Images

Finance

How Nimbus’ focus on internal pipeline could point to long-awaited exit

Oct 19, 2020 | 10:00 PM GMT

With a new $60 million crossover round and an internal pipeline moving through the clinic, computational chemistry company Nimbus may be nearing a liquidity event for investors who have stuck with the company since its inception in 2009.

The structure-based drug discovery company raised the funds Oct. 14 from a syndicate that included crossover investors RA Capital

Read the full 784 word article

How to gain access

Continue reading with a
two-week free trial.